Scotiabank Initiates Coverage On Tempest Therapeutics with Sector Outperform Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating and a price target of $13.

March 14, 2024 | 9:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank initiated coverage on Tempest Therapeutics with a Sector Outperform rating and a price target of $13.
The initiation of coverage by Scotiabank with a Sector Outperform rating and a price target significantly higher than its current trading price is likely to generate positive investor sentiment towards TPST. This could lead to an increase in demand for TPST shares, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100